Dev

Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients Investments > €500k European Commission Motor neurone diseases 2016    

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

European Prevention of Alzheimer’s Dementia Consortium (EPAD) Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Non-Invasive In-Vivo Histology in Health and Disease Using Magnetic Resonance Imaging (MRI) Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Brain Microcirculation : Numerical simulation for inter-species translation with applications in human health Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Understanding death-receptor signaling and physiology in the nervous system: A roadmap for the development of new treatments to neurodegenerative diseases and neurotrauma Investments > €500k European Commission Neurodegenerative disease in general 2016    

Toxic protein aggregation in neurodegeneration Investments > €500k European Commission Neurodegenerative disease in general 2016    

C9orf72 repeat expansion in FTD/ALS – from mechanisms to therapeutic approaches Investments > €500k European Commission Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

From zebrafish to man Modifying amyotrophic lateral sclerosis (ALS): translation of biology into therapy Investments > €500k European Commission Motor neurone diseases 2016